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Abstract
Background: Waitlisted kidney transplant patients suffer from excess cardiovascular events. The benefits of 
regular cardiac investigations, potentially harmful and expensive, are unknown. We investigate the 
effectiveness of a cardio-renal MDT in managing high cardiovascular risk waitlisted transplant patients to 
prevent events and enable transplantation. 
Methods: Clinical outcomes in waitlisted transplant candidates managed by our cardio-renal MDT protocol 
were compared against our standard protocol. Data compared include the transplantation, event, and death 
rates, cost of cardiac investigations and procedures, and graft, patient survival, and re-hospitalisation rates 
in transplanted patients.
Results: 207 patients were studied (81 standard, 126 cardio-renal MDT). Over 2.7 years, the cardio-renal 
MDT protocol transplanted more patients than the standard group (35% vs. 21%; p=0.02). The managing 
cost per patient per year was higher in the standard group (£692 vs. £610). This was driven by more 
echocardiograms and more tests per patient in the standard group (p<0.01). There was no difference in 
adverse events or death. There was no difference in re-hospitalisation, graft or patient survival rate in 
transplanted patients.  
Conclusions: Our cardio-renal MDT was effective in managing high-risk kidney transplant candidates with 
greater rates of transplantation and low rates of events at a lower cost.  
Key words: end stage renal disease, chronic kidney disease, cardiovascular disease, kidney transplantation, 
cardiorenal syndrome
Background
Patients on the kidney transplant waitlist suffer from multiple co-morbidities associated with end-
stage renal disease (ESRD). This incurs a high cardiovascular event and mortality rate despite already 
having undergone cardiovascular evaluation to be listed for transplantation [1, 2]. Currently, there is no 
established protocol on when and how to utilise cardiac investigations in waitlisted transplant candidates. 
Indeed, cardiac investigations may be used to screen for patients with asymptomatic coronary artery disease 
(CAD). This may enable the correction of it before being listed again. Occasionally, investigated patients 
are deemed unsuitable due to unmodifiable cardiac risk and poor prognosis and are subsequently removed A
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from the waitlist. This is to prevent premature cardiovascular mortality at transplantation or soon after. 
However, screening is potentially harmful and is costly. 
The lack of evidenced-based screening methods prompted the start of two randomised controlled 
trials aiming to determine the optimal strategy to monitor and maintain cardiac fitness in waitlisted patients. 
The CADScreening trial (NCT02082483) is investigating the benefits of routine screening for CAD in 
waitlisted patients with myocardial perfusion scintigraphy (MPS) or dobutamine stress echo (DSE) versus 
selective screening based on symptoms. The CARSK trial (NCT03674307) tests the hypothesis that no 
further screening after waitlist entry is non-inferior to regular screening for CAD in preventing adverse 
cardiac events. 
            As a unit, we have a risk stratification protocol for patients before waitlisting for kidney 
transplantation. This protocol is relatively successful, evidenced by low peri-transplant death and cardiac 
event rates [3]. Our protocol introduced a cardio-renal multi-disciplinary team (MDT) meeting evaluation 
for all patients on the transplant waitlist. This study aims to investigate the effectiveness of a structured 
cardio-renal MDT in managing high cardiovascular risk patients on the kidney transplant waitlist to prevent 
pre-/peri-transplant cardiovascular events and enabling successful transplantation. This includes 
rationalising cardiac investigations in such patients to provide safe kidney transplantation yet minimize 
invasive investigations. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved
Materials and methods
            This study was an observational audit that compared two cohorts of patients. The control group was 
managed by our standard protocol, while our cardio-renal MDT managed the interventional cohort. All 
patients on the kidney transplant waitlist at St. George’s University Hospitals NHS Foundation Trust 
between 1 October 2011 and 31 September 2014 were included in the standard protocol group. Patients 
were followed from 1 October 2011 to 30 April 2016. All patients on the kidney transplant waitlist at St. 
George’s University Hospitals NHS Foundation Trust between 1 October 2014 and 30 September 2017 
were included in the cardio-renal MDT group. Patients were followed from 1 October 2014 to 11 May 
2019. This study was approved by the hospital’s Clinical Effectiveness and Audits Committee. As it is an 
audit, all data is anonymised, and informed consent was not necessary. 
Prior to waitlisting, each patient underwent cardiac investigation and risk stratification according to 
our unit protocol [3]. Patients were classified as either high-risk (>60 years old or significant CAD 
[previous myocardial infarction, angiogram with >50% stenosis] or previous cerebrovascular accident 
(CVA) or significant peripheral vascular disease or had diabetes mellitus) or low-risk (those without 
defined high-risk features).
Waitlisted patients managed with our standard protocol involved being closely followed by their 
primary nephrologist. The primary nephrologist would determine the initiation of any inter-disciplinary 
management with cardiology regarding transplant needs. The decision to review patients and examine them 
in a clinical setting was determined based on clinical need by individual nephrologists and cardiologists. 
This includes decisions involving the evaluation of patients using cardiac testing.
            Waitlisted patients managed with our cardio-renal MDT protocol were closely followed by a 
primary nephrologist and cardiologist. Patients were also reviewed and examined in a clinical setting based 
on clinical need throughout the follow-up period. However, patients were additionally routinely discussed 
in cardio-renal MDT meetings that occurred 4 times a year. Twelve to 14 patients were discussed in a 
single meeting with each patient discussed for approximately 5 minutes. The meetings were attended by 
kidney transplant nurses, 1 interventional cardiologist, 1 non-interventional cardiologist and nephrologists 
caring for the patients. 
           High-risk patients were routinely discussed every 2 years since waitlisted while low-risk patients 
were routinely discussed every 5 years since waitlisted. Any patient deemed complex by a nephrologist or 
cardiologist where the decision to maintain waitlist status was not straightforward were discussed in 
addition to the specified routine intervals. For example, patients with a very complicated history of CAD or 
were suffering from angina at the time. 
            The meeting would begin with the nephrologists presenting the patient’s relevant clinical findings 
and the patient’s specific concerns if necessary. The cardiologists would then present all the cardiac 
investigations. A
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Each patient discussion leads to 3 possible outcomes. First, a patient is deemed too high-risk for 
surgery and was advised to be removed from the list. The second outcome is to re-evaluate a currently 
asymptomatic patient on the waitlist, usually with a non-invasive test. The third outcome is the decision to 
investigate a patient with complex findings or is currently symptomatic. This often prompted advice for 
coronary angiogram (CA) or invasive cardiac intervention.
The following are the definitions of a positive test: echocardiogram (echo) (wall motion or valvular 
abnormality), exercise stress echocardiogram (ESE) (≥2x17 segments abnormal), DSE (≥2x17 segments 
abnormal), CA (>50% stenosis in any vessel). 
Statistical analyses were conducted using IBM SPSS version 25.0 (SPSS Inc., Chicago, IL, USA). 
Kaplan-Meier curves and Cox regression analysis were used to compare the cardiac event rates between 
different groups, including diabetics vs. non-diabetics and those who tested DSE positive vs. DSE negative. 
Events included acute coronary syndrome, CVA, percutaneous coronary intervention (PCI), coronary artery 
bypass graft (CABG), or death. 
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Results
Baseline characteristics of patients discussed
A total of 81 patients were included in the standard protocol group. There were 126 kidney 
transplant candidates included in the cardio-renal MDT group. Twenty-nine patients were discussed more 
than once, which resulted in 164 cardio-renal MDT meeting patient episodes. Table 1 shows the baseline 
characteristics of all patients. There was no difference in any clinical or laboratory characteristics between 
groups. Four patients had previous renal transplants in the standard protocol group. Two patients had 
previous renal transplants in the cardio-renal MDT group. 
Procedures performed
           Table 2 compares the type and number of cardiac procedures performed between groups. 
Throughout the study period, 114 and 127 cardiac investigations were done in the standard and cardio-renal 
MDT groups. Twenty-three percent of patients received no cardiac intervention, 33% had a single 
intervention, and 43% had multiple interventions in the standard protocol group. Thirty-five percent of 
patients received no cardiac intervention, 44% had a single intervention, and 21% had multiple 
interventions in the cardio-renal MDT group. In the standard protocol group, more patients underwent 
multiple interventions (43% vs. 21%; p<0.01). There was also more echo performed in the standard 
protocol group. There was no difference in the number of DSE, ESE, CA, PCI, or CABG performed. 
In the cardio-renal MDT group, 96 cardiac procedures were performed as a direct outcome of the 
MDT discussion. Nine echo, 5 ESE, and 61 DSE were conducted in the repeat evaluation of asymptomatic 
patients (Figure 1). Thirteen CA, 4 PCIs, and 4 CABGs were conducted in the immediate evaluation of 
symptomatic patients (Figure 2). Non-invasive testing in asymptomatic patients (echo, ESE, DSE) resulted 
in a further 19 CA, 10 PCI, and 2 CABG (Figure 1). 
Patients removed from the transplant waitlist
            In the standard protocol group, 12 patients were deemed unsuitable for transplantation and removed 
from the transplant waitlist. One patient died of a myocardial infarction at the end of follow-up. In the 
cardio-renal MDT group, 7 patients were deemed unsuitable for transplantation and were removed from the 
transplant waitlist. Six patients were still alive at the end of follow-up. One patient died of myocardial A
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infarction. Our cardio-renal MDT removed fewer patients based on cardiovascular risk compared to our 
standard protocol (7 vs. 12; p=0.02). 
Clinical outcomes – transplantation rate and adverse events
            Table 3 compares clinical outcomes between groups. Importantly, more patients were transplanted 
over the follow-up period if they were managed in the cardio-renal MDT group as opposed to the standard 
protocol group (35% vs. 21%; p=0.02). There was no difference in mortality or the number of adverse 
events between groups. 
In the standard protocol group, there was no difference between transplanted and non-transplanted 
patients with respect to the following: age (p=0.16), body mass index (BMI) (p=0.09), diabetes status 
(p=0.81), smoking status (p=0.15), gender (p=0.33), hypertension (p=0.23), haemoglobin (p=0.54), urea 
(p=0.92), parathyroid hormone (PTH) (p=0.23), phosphate (p=0.21), ferritin (p=0.80), length of follow-up 
(p=0.39), or positive DSE (p=0.09). Transplanted patients had higher creatinine (p=0.04) and cholesterol 
(p=0.01) and lower calcium (p<0.01) at baseline. There was no difference in those who experienced events 
and those who did not with respect to the following: age (p=0.17), BMI (p=0.30), diabetes status (p=0.59), 
smoking status (p=0.97), gender (p=0.23), hypertension (p=0.90), haemoglobin (p=0.43), creatinine 
(p=0.78), urea (p=0.90), PTH (p=0.94), calcium (p=0.71), phosphate (p=0.86), ferritin (p=0.07),  or 
positive DSE (p=0.88). Those who suffered events had higher cholesterol (p=0.01) and shorter follow-up 
(p<0.01). 
In the cardio-renal MDT group, there was no difference between transplanted and non-transplanted 
patients with respect to the following: age (p=0.83), body mass index (BMI) (p=0.29), diabetes status 
(p=0.85), smoking status (p=0.45), gender (p=0.08), hypertension (p=0.48), haemoglobin (p=0.01), 
creatinine (p=0.36), urea (p=0.10), cholesterol (p=0.98), parathyroid hormone (PTH) (p=0.52), calcium 
(p=0.33), phosphate (p=0.71), ferritin (p=0.52), length of follow-up (p=0.19), or positive DSE (p=0.43). 
There was no difference in those who experienced events and those who did not with respect to the 
following: age (p=0.65), BMI (p=0.75), smoking status (p=0.11), gender (p=0.20), hypertension (p=0.75), 
creatinine (p=0.81), urea (p=0.18), cholesterol (p=0.31), PTH (p=0.42), calcium (p=0.45), phosphate 
(p=0.80), ferritin (p=0.10), or positive DSE (p=0.18). There were more diabetics with events (p=0.01) and 
those with events had lower haemoglobin (p=0.02) and shorter follow-up (p<0.00).
Diabetics were more likely to experience events as shown by the Kaplan-Meier analysis in Figure 3 
(Log-rank test; p<0.01) and was the only significant variable on Cox regression when adjusted for age, 
gender, hypertension, cholesterol, and BMI (p=0.01). Those with positive DSE results tended to have more 
events (Figure 4), but this was not statistically significant (Log-rank test; p=0.09). A
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Clinical outcomes – morbidity and mortality in transplanted patients
Table 4 summarizes the long term clinical outcomes in transplanted patients between the two 
groups. There was no difference in hospitalisation rates 1 year after transplantation between groups. In the 
cardio-renal MDT group, 18 patients were hospitalised at least once 1 year after transplantation. There were 
23 hospitalisations, of which 4 were due to cardiac causes. Three were due to acute coronary syndrome, 
and 1 was due to heart failure exacerbation. In the standard protocol group, 7 patients were hospitalised at 
least once 1 year after transplantation. There were 9 hospitalisations, of which none were due to cardiac 
causes. There was no difference in the number of total hospitalisations between the two groups (p=0.67). 
There was no difference in graft or patient survival at 1 or 2 years after transplantation between groups. 
Cost analysis
        Tables 5 and 6 show the cost of investigations in the standard protocol and cardio-renal MDT protocol 
groups [4]. Notably, cardiac stress testing is significantly cheaper than CA, PCI, or CABG. The total cost 
of cardiac evaluation and intervention for maintaining 81 patients active on the list under the standard 
protocol was £151,483 or £692/patient/year. The cost of maintaining patients under the cardio-renal MDT 
protocol was £207,652. The cost at £610/patient/year is more economical compared to patients managed 
under the standard protocol.
Peri-transplant event rates
In the cardio-renal MDT group, 2 patients (6%) suffered from adverse events within thirty days of 
kidney transplant surgery, as defined previously [5, 6]. One patient had atypical chest pain and a troponin T 
rise 13 days after surgery. While the other suffered ischaemic chest pain 5 days after surgery. Both were 
treated conservatively. No peri-transplant events occurred in patients managed with the standard protocol. 
Discussion
This study demonstrates the efficacy of a cardio-renal MDT in managing high cardiovascular risk 
patients on the kidney transplant waitlist. Over the same duration of 2.7 years, the cardio-renal MDT group 
transplanted more patients than the standard protocol group (35% vs. 21%; p=0.02) with only 2 peri-
operative events. No difference existed between transplanted and non-transplanted patients regarding 
baseline clinical or laboratory characteristics in the cardio-renal MDT group. In the standard protocol 
group, those who were transplanted had higher creatinine and cholesterol and lower calcium, demonstrating 
that those who were transplanted had worse renal function and metabolic risk factors. There was no A
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difference in adverse events or mortality between the two groups. There was also no difference in 
morbidity or mortality in transplanted patients, namely patient and graft survival and re-hospitalisation rate. 
Importantly, the cost of cardiovascular investigations and interventions was cheaper in the cardio-renal 
MDT group at £610/person/year vs. £692/person/year in the standard protocol group. The increased cost in 
the standard protocol group was driven by a higher number of echo conducted and a greater number of 
patients undergoing multiple cardiac tests. Ultimately, the cardio-renal MDT conducted a more tailored 
cardiac evaluation, which omitted unnecessary echo. The cardio-renal MDT identified 7 very high-risk 
patients on the list and removed them. Only 1 of these patients died upon follow-up. In doing so, we were 
able to prevent the high likelihood of these patients suffering from peri-operative adverse events. 
Additionally, this allowed donor kidneys to be allocated to more suitable candidates who would benefit. 
Overall, the cardio-renal MDT accepted a higher risk patient population where it refused fewer patients for 
transplantation compared to our standard protocol. Having a vested cardiology group involved allowed 
these patients to be transplanted without suffering from worse post-transplant adverse outcomes. 
Presumably, increased multi-disciplinary team working pre-transplantation allowed for timelier and 
directed cardiac care post-transplantation. The average cost over 2.7 years to maintain the kidney transplant 
waitlist with the cardio-renal MDT protocol was £1,634 per patient. DSE costs 10x less than CA, with PCI 
and CABG being even more expensive. Thus, the DSE was useful in ruling out disease to prevent 
conducting more invasive and costly cardiac investigations and procedures. Diabetics on the kidney 
transplant waitlist have a 2% higher mortality rate per year compared to their non-diabetic counterparts [7]. 
This is consistent with our study, where diabetics suffered more adverse events. We also showed that 
patients with positive DSE tended to have more events, but this was not statistically significant. This agrees 
with previous studies done [3, 8]. 
The optimal screening method and modality to optimise cardiovascular risk in transplant 
candidates is not agreed upon. The sensitivity and specificity of DSE in detecting underlying CAD in 
patients with ESRD has been reported to range from 0.44-0.89 and 0.71-0.94, respectively [9]. In 
comparison, the sensitivity and specificity of MPS were 0.29-0.92 and 0.67-0.89, respectively [9]. Indeed, 
it has been shown that MPS was only useful for cardiovascular risk stratification in kidney transplant 
candidates that were determined to be intermediate-risk, not low or high-risk [10]. In light of this, Mann et 
al. argued that CA is more useful in assessing cardiovascular risk in transplant candidates [11]. 
The contrasting approach by Kumar’s group versus Kasiske’s group is an example of the lack of 
clarity to manage these patients best [12, 13]. Kumar et al. investigated cardiac survival after pre-emptive 
coronary angiography in ESRD patients before transplantation [12]. Their pre-transplant practice involves 
an aggressive approach to invasive cardiac investigations in transplant candidates, where screening CA is 
conducted liberally, including in all patients >50 years old or with diabetes. In patients who went CA 
screening and were deemed suitable for waitlist entry, overall survival three years after CA was 97.2% in A
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those eventually transplanted. At the same time, it was 80.7% in those still awaiting transplantation [12]. 
Ultimately, survival was comparable to our approach, where screening was not restricted to solely invasive 
and expensive CA. In contrast, Kasiske et al. found that a risk-stratified approach to screening waitlisted 
kidney transplant candidates effectively avoided unnecessary testing [13]. In their retrospective review of 
514 patients, 43.6% were categorised as low risk and did not undergo cardiac screening [13]. In these 
patients, the incidence of an ischaemic heart disease (IHD) event after waitlisting (before or after 
transplantation) was 0.5% at 1 year, 3.5% at 3 years, and 5.3% at 5 years [13]. 56.4% of patients were 
categorised as high-risk and underwent non-invasive stress testing or coronary angiography, which resulted 
in 6.2% and 2.8% of these patients to undergo prophylactic angioplasty or CABG, respectively [13]. 
Overall, the incidence of an IHD event after listing in these patients was 3.5% at 1 year, 8.1% at 3 years, 
and 19.7% at 5 years [13]. Importantly, of the 68 patients who suffered from an IHD event after being 
waitlisted, 80.6% underwent screening [13]. Yet, only 9% of patients screened underwent coronary 
angioplasty or CABG [13]. The authors concluded that in light of the relatively low proportion of screened 
patients who subsequently had an intervention, screening might not be cost-effective in preventing IHD 
events. Regardless, comparing these two contrasting approaches to our study, our cardio-renal MDT 
approach was effective and cost-sensitive, considering the transplantation, event, and mortality rate. 
Teamwork between cardiologists, nephrologists, and kidney transplant nurses improved care by 
aggregating and combining a greater amount of knowledge and expertise to make targeted clinical 
decisions and execute tasks more efficiently. This was evidenced by conducting fewer investigations that 
lowered cost, and transplanting more patients compared to our standard protocol over the same period. 
Therefore, it may be more useful to evaluate patients using a multi-modal approach rationalised in a 
structured MDT discussion instead of restricting assessment using a single pre-specified cardiac 
investigation or withholding screening altogether. It is important to stress that the annual mortality rate of 
those who remained on our waiting list is below national averages when managed with the standard or 
cardio-renal MDT protocol [7]. 
Previously, it has been shown that a multi-disciplinary approach can be useful in cardiac risk 
stratifying kidney transplant candidates [14]. Depending on whether patients were determined to be low, 
intermediate, or high-risk, cardiac testing was performed, which may include an exercise stress test, 
myocardial perfusion imaging, or CA [14]. Similar to our study, any abnormality on non-invasive testing 
led to more invasive evaluation and/or intervention. However, there was no mention of the long term 
outcomes resulting from this multi-disciplinary approach, including the transplantation, event, and 
mortality rate. Furthermore, a cost-analysis was not done. Therefore, it is difficult to determine the actual 
efficacy of the study’s approach. 
Recently, the Cardiovascular Work Group of the Kidney Pancreas Community of Practice of the 
American Society of Transplantation aimed to summarise key factors that may contribute to sub-optimal A
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cardiovascular care in kidney transplant patients, including during the period of active transplant listing 
[15]. They stressed that despite the guidance available endorsed by organisations such as the American 
College of Cardiology, the American Heart Association, the National Kidney Foundation, and the 
American Society of Transplantation, the management of cardiovascular risk pre- and post-kidney 
transplantation vary widely amongst different transplant centers [15-17].
Several reasons may explain this. Firstly, there is a paucity of robust data on the optimal screening 
and management methods for CAD in CKD, as well as the optimal frequency to reassess coronary ischemia 
in asymptomatic patients [15]. It is unsurprising that this is the case, considering that CKD patients are 
often excluded from major cardiovascular trials. Screening for cardiac disease in kidney transplant 
candidates may be important for two reasons. Firstly, to identify patients with asymptomatic CAD to 
enable either the correction of it or removal of the patient from the list, with the end goal of preventing 
premature cardiovascular mortality at transplantation or soon after. Secondly, to avoid the misallocation of 
scarce donor allografts into those who experience early mortality. 
Another reason is that the waitlisted patient invariably falls into a “no man’s” land, where the 
responsibility of cardiovascular risk ownership is unclear in the setting of a fragmented model of care 
consisting of the transplant nephrologist, the evaluating cardiologist, and the referring nephrologist [15]. 
Thus, the Cardiovascular Work Group urge the development of proactive care models and cardiovascular 
screening trials to address the waitlisted population of patients [15]. The CADScreening (NCT02082483) 
and CARSK trial (NCT03674307) will hopefully provide greater insight into the best way to detect 
cardiovascular disease in such patients. In the meantime, our study shows that a structured cardio-renal 
MDT meeting is useful in rationalising cardiac investigations in waitlisted candidates. Furthermore, our 
protocol replaces the fragmented care actively waitlisted patients experience with a more holistic approach 
where the whole multi-disciplinary team shares responsibility for cardiovascular risk optimisation.
Limitations
            Our study was an observational study without randomisation. Hence, it is hypothesis generating and 
may need data from a prospective randomised study before being universally accepted. 
Conclusions
This is the first study to have evaluated the cost and effectiveness of a standardised cardio-renal 
MDT meeting in managing cardiac risk amongst kidney transplant candidates. Our cardio-renal MDT 
managed a group of very high-risk patients at a lower cost but was able to transplant more patients over the 
same follow-up period compared to our standard protocol. The overall cost was £610/year/patient in the 
cardio-renal MDT group, and this was achieved using mostly non-invasive cardiac tests and limiting 
invasive cardiac testing or intervention.A
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List of abbreviations
ESRD: end-stage renal disease
CAD: coronary artery disease
MPS: myocardial perfusion scintigraphy 
DSE: dobutamine stress echo
MDT: multi-disciplinary team 
CVA: cerebrovascular accident
CA: coronary angiogram
Echo: echocardiogram
ESE: exercise stress echocardiogram
PCI: percutaneous coronary intervention
CABG: coronary artery bypass graft
IQR: interquartile range
BMI: body mass index 
PTH: parathyroid hormone
LVSF: left ventricular systolic function
LVEF: left ventricular ejection fraction
MRI: magnetic resonance imaging
IHD: ischaemic heart disease
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Table 1. Baseline clinical and laboratory characteristics. 
 
Characteristic Standard protocol (N=81) Cardio-renal MDT protocol (N=126) P-value 
Age 59.42 (11.14) 61.15 (8.12) 0.16 
Body mass index 29.08 (5.76) 28.15 (4.6) 0.19 
Male 44 (54.32%) 75 (59.52%) 0.42 
Diabetes mellitus 45 (55.56%) 77 (61.11%) 0.42 
Hypertension 76 (93.83%) 121 (96.03%) 0.37 
Smoking status past/present/never 47/9/25 (58.02%/11.11%/30.86%) 70/12/44 (55.56%/9.52%/34.92%) 0.82 
Haemoglobin (g/L) 108.07 (17.15) 108.18 (14.63) 0.96 
Cholesterol (mmol/L) 4.08 (1.19) 4.02 (1.16) 0.69 
Parathyroid hormone (pmol/L) 47.72 (58.04) 44.54 (39.20) 0.62 
Calcium (mmol/L) 2.20 (0.18) 2.34 (1.64) 0.44 
Phosphate (mmol/L) 1.48 (0.38) 1.50 (0.32) 0.77 
Ferritin (mcmol/L) 312.60 (343.73) 385.97 (337.08) 0.12 
 
Legend: MDT multi-disciplinary team. Data presented as mean (standard deviation) or number 
(percentage %) 
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Table 2. Type and number of cardiac procedures performed. 
 
Procedure Standard protocol (N=81) Cardio-renal MDT protocol (N=126) P-value 
Echocardiogram 30 (37.04%) 9 (7.14%) <0.01 
Exercise stress echocardiogram 0 5 (3.97%) 0.11 
Dobutamine stress echocardiogram 49 (60.49%) 61 (48.41%) 0.08 
Coronary angiogram 20 (24.69%) 32 (25.40%) 0.29 
Percutaneous coronary intervention 9 (11.11%) 14 (11.11%) 0.52 
Coronary artery bypass graft 6 (7.41%) 6 (4.76%) 0.79 
 
Legend: Data presented as number (percentage %) 
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Table 3. Long term clinical outcomes. 
 
Outcome Standard protocol (N=81) Cardio-renal MDT protocol (N=126) P-value 
Transplanted 17 (20.99%) 44 (34.92%) 0.02 
Adverse event 29 (35.80%) 42 (33.33%) 0.66 
Death 8 (9.88%) 16 (12.69%) 0.21 
 
Legend: Data presented as number (percentage %) 
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Table 4. Long term clinical outcomes in transplanted patients. 
 
Outcome Standard protocol (N=17) Cardio-renal MDT protocol (N=44) P-value 
Hospitalised 1 year after transplantation 7 (41.18%) 18 (40.91%) 0.99 
Graft survival 1 year after transplantation 17 (100%) 42 (95.45%) 0.37 
Graft survival 2 years after transplantation 16 (94.11%) 42 (95.45%) 0.83 
Patient survival 1 year after transplantation 17 (100%) 43 (97.72%) 0.53 
Patient survival 2 years after transplantation 16 (94.11%) 43 (97.72%) 0.48 
 
Legend: Data presented as number (percentage %) 
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Table 5. Cost for procedures calculated from NHS best practice tariffs in the standard protocol group. 
 
Procedure Number Cost per procedure (£) Cost (£) 
Echocardiogram  30 58 1,740 
Exercise stress echocardiogram  0 250 0 
Dobutamine stress echocardiogram 49 250 12,250 
Coronary angiogram 20 2,751 55,020 
Percutaneous coronary intervention 9 4,025 36,225 
Coronary artery bypass graft 6 7,708 46,248 
Total cost   151,483 
Cost per patient    1,870 
Cost per patient per year    692 
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Table 6. Cost for procedures calculated from NHS best practice tariffs in the cardio-renal MDT 
protocol group. 
 
Procedure Number Cost per procedure (£) Cost (£) 
Echocardiogram  9 58 522 
Exercise stress echocardiogram  5 250 1,250 
Dobutamine stress echocardiogram 61 250 15,250 
Coronary angiogram 32 2,751 88,032 
Percutaneous coronary intervention 14 4,025 56,350 
Coronary artery bypass graft 6 7,708 46,248 
Total cost   207,652 
Cost per patient    1,648 
Cost per patient per year    610 
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